Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cyclopropane Carboxylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.52 |
| ▸ | GABRE | P78334 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropane Carboxylic Acid SCHEMBL21581961 | 0.90 | TSHR (0.55) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Methyl Alcohol SCHEMBL15536588 | 0.90 | TSHR (0.55) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL26833 | 0.89 | TSHR (0.61) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Cyclopropane Carboxylic Acid SCHEMBL10800712 | 0.89 | — | — | |
| Cyclopropane Carboxylic Acid SCHEMBL32889332 | 0.89 | — | — | |
| SCHEMBL329128 | 0.89 | TSHR (0.61) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Cyclopropane Carboxylic Acid SCHEMBL5499291 | 0.89 | — | — | |
| SCHEMBL36093 | 0.89 | TSHR (0.61) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Cyclopropane Carboxylic Acid SCHEMBL4643 | 0.89 | — | — | |
| SCHEMBL196124 | 0.89 | TSHR (0.61) | TSHRGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414461-A4 | PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1056341-A4 | METHOD AND APPARATUS FOR THE PREPARATION OF KETONES | EAGLEVIEW TECHNOLOGIES INC (US) | 2005-05-11 | — | — | EP | disclosed |
| EP-1414461-A1 | PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD | Bristol-Myers Squibb Company (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6670380-B2 | For therapy of insulin resistance, hyperglycemia, hyperinsulinemia, or elevated blood levels of free fatty acids or glycerol, obesity, hypertriglyceridemia, inflammation, atherosclerosis, diabetic retinopathy, diabetic neuropathy | BRISTOL-MYERS SQUIBB CO. | 2003-12-30 | — | — | US | disclosed |
| EP-1343763-A1 | PYRODONE DERIVATIVES AS AP2 INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003006023-A1 | PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
| US-20020193638-A1 | Method and apparatus for the preparation of ketones | EAGLEVIEW TECHNOLOGIES, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6495696-B1 | FIRST CARBOXYLIC ACID OR ALDEHYDE OR DERIVATIVES AND A SECOND CARBOXYLIC ACID IN THE RATIO OF 1:2 TO 1:20, PASSING THROUGH ACATALYTIC BED AT A TEMPERATURE OF 350-500 DEGREES C AT WEIGHT HOURLY SPACE VELOCITY OF > 2 | EAGLEVIEW TECHNOLOGIES, INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1253925-A1 | TETRAHYDROPYRIMIDONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD | Bristol-Myers Squibb Company (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1121129-A4 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL MYERS SQUIBB CO (US) | 2002-10-16 | — | — | EP | disclosed |
| EP-1181014-A4 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2002040448-A1 | PYRIDONE DERIVATIVES AS AP2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-23 | — | — | WO | disclosed |
| US-6392099-B1 | FROM CARBOXYLIC ACID OR ALDEHYDE | EAGLEVIEW TECHNOLOGIES, INC. | 2002-05-21 | — | — | US | disclosed |
| EP-1181014-A1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-1121129-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001054694-A1 | TETRAHYDROPYRIMIDONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-1056341-A1 | METHOD AND APPARATUS FOR THE PREPARATION OF KETONES | Eagleview Technologies, Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-2000059506-A1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000030448-A1 | METHOD AND APPARATUS FOR THE PREPARATION OF KETONES | EAGLEVIEW TECHNOLOGIES, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000015229-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193638-A1 | Method and apparatus for the preparation of ketones | BCKDK, PCCA, HOGA1 | TSHR 1759/4885GABRP 2912/4885GABRD 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.